Terodiline hydrochloride
Terodiline hydrochloride结构式
|
常用名 | Terodiline hydrochloride | 英文名 | Terodiline hydrochloride |
|---|---|---|---|---|
| CAS号 | 7082-21-5 | 分子量 | 317.89600 | |
| 密度 | N/A | 沸点 | 390.9ºC at 760 mmHg | |
| 分子式 | C20H28ClN | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 168.9ºC | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
|
Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.
J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999) Terodiline was widely prescribed for urinary incontinence before reports of adverse cardiac effects that included bradycardia, QT lengthening, and ventricular tachyarrhythmia. The present study on guinea pig papillary muscles and ventricular myocytes was unde... |
|
|
Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.
Gen. Pharmacol. 30(1) , 137-42, (1998) 1. NS-21 [(+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate], its active metabolite, RCC-36, and terodiline, are mixed anticholinergic-Ca2+ antagonistic drugs. Among them, terodiline has been s... |
|
|
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000) Terodiline has concentration dependent QT prolonging effects and thus the potential for cardiotoxicity. Pharmacogenetic variation in terodiline metabolism could be responsible for cardiotoxicity. We sought to determine whether CYP2D6 (debrisoquine hydroxylase... |
|
|
Inhibition of cardiac inward-rectifier K+ current by terodiline.
Eur. J. Pharmacol. 370(3) , 319-27, (1999) The antispasmodic agent terodiline has cardiotoxic effects that include QT lengthening. To determine whether inhibition of inwardly-rectifying K+ current (I(K1)) might be a factor in the cardiotoxicity, we measured I(K1) in guinea pig ventricular myocytes. Te... |
|
|
Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.
Xenobiotica 31(8-9) , 633-50, (2001) 1. Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD). TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfen... |
|
|
In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.
J. Cardiovasc. Pharmacol. 48(5) , 199-206, (2006) Terodiline and tolterodine are drugs used to treat urinary incontinence. Terodiline was removed from the market in 1991 for proarrhythmia, whereas tolterodine has a generally benign clinical cardiac profile. To assess differences in the electrophysiologic act... |
|
|
Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline.
Naunyn Schmiedebergs Arch. Pharmacol. 355(5) , 651-8, (1997) Terodiline, an anticholinergic drug with a Ca2+ blocking action, is thought to be associated with torsade de pointes, a serious ventricular tachycardia. NS-21 is a newly developed drug for the treatment of urinary frequency and urinary incontinence and it has... |
|
|
Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline.
Arzneimittelforschung 48(10) , 1012-8, (1998) Racemic oxybutynin (CAS 1508-65-2) is used clinically to treat urinary incontinence and reportedly undergoes N-deethylation to metabolites R- and/or S-desethyloxybutynin. To assess the role of these metabolites in the therapeutic effects of oxybutynin, the an... |
|
|
Agents for the treatment of overactive detrusor. V. Synthesis and inhibitory activity on detrusor contraction of N-tert-butyl-4,4-diphenyl-2-cyclopentenylamine.
Chem. Pharm. Bull. 44(10) , 1858-64, (1996) N-tert-Butyl-4,4-diphenyl-2-cyclopentenylamine ((+/-)-3) was designed to restrict the conformation of terodiline 1 and was synthesized in a 6-step approach starting with diphenylacetaldehyde (10) or in a 4-step approach starting with 2,2-diphenyl-4-pentenoic ... |
|
|
Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells.
Naunyn Schmiedebergs Arch. Pharmacol. 355(5) , 659-66, (1997) The inhibitory effects of NS-21, a newly developed drug for the treatment of urinary frequency and urinary incontinence, and its active metabolite, RCC-36, on L-type Ca2+ currents (ICa) in guinea pig detrusor smooth muscle cells have been compared to those of... |